The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase of an escalating battle for control of the obesity drug market.
The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback